Allena Pharmaceuticals Inc (NASDAQ:ALNA) has earned an average recommendation of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $9.75.
ALNA has been the topic of a number of recent analyst reports. Wedbush reaffirmed a “buy” rating and set a $26.00 target price on shares of Allena Pharmaceuticals in a research report on Tuesday, June 2nd. HC Wainwright initiated coverage on Allena Pharmaceuticals in a research report on Monday, June 1st. They set a “buy” rating and a $10.00 target price on the stock. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $8.00 target price on shares of Allena Pharmaceuticals in a research report on Wednesday, July 15th. Roth Capital reaffirmed a “market perform” rating and set a $11.00 target price on shares of Allena Pharmaceuticals in a research report on Wednesday, July 15th. Finally, Zacks Investment Research upgraded Allena Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Thursday, May 21st.
Several hedge funds have recently modified their holdings of the company. Wedbush Securities Inc. grew its holdings in shares of Allena Pharmaceuticals by 103.5% during the second quarter. Wedbush Securities Inc. now owns 49,150 shares of the company’s stock valued at $78,000 after buying an additional 25,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Allena Pharmaceuticals by 103.0% during the 4th quarter. Geode Capital Management LLC now owns 105,854 shares of the company’s stock worth $288,000 after acquiring an additional 53,719 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Allena Pharmaceuticals by 91.2% during the 4th quarter. Renaissance Technologies LLC now owns 241,700 shares of the company’s stock worth $660,000 after acquiring an additional 115,300 shares in the last quarter. Finally, Morgan Stanley lifted its position in shares of Allena Pharmaceuticals by 56.1% during the 1st quarter. Morgan Stanley now owns 1,253,847 shares of the company’s stock worth $1,207,000 after purchasing an additional 450,688 shares during the last quarter. Institutional investors and hedge funds own 58.65% of the company’s stock.
Allena Pharmaceuticals (NASDAQ:ALNA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.14. On average, equities analysts forecast that Allena Pharmaceuticals will post -1.07 earnings per share for the current year.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Story: Consumer Price Index (CPI)
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.